Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

According to Lee, a dominant and recurrent theme emerging from several key presentations and discussions at ASH 2025 was the ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

Orlowski serves as chairman, Ad Interim, and director of Myeloma in the Departments of Lymphoma/Myeloma and Experimental ...

Legend Biotech Corp (NASDAQ:LEGN) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, ...

At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by The Institute of Cancer ...